Literature DB >> 25451212

Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.

Akina Harada1, Kazunori Suzuki1, Shotaro Miura1, Tomoaki Hasui1, Naomi Kamiguchi2, Tsuyoshi Ishii3, Takahiko Taniguchi1, Takanobu Kuroita1, Akihiro Takano4, Vladimir Stepanov4, Christer Halldin4, Haruhide Kimura5.   

Abstract

INTRODUCTION: Phosphodiesterase 10A (PDE10A) is a dual-substrate PDE that hydrolyzes both cAMP and cGMP and is selectively expressed in striatal medium spiny neurons. Recent studies have suggested that PDE10A inhibition is a novel approach for the treatment of disorders such as schizophrenia and Huntington's disease. A positron emission tomography (PET) occupancy study can provide useful information for the development of PDE10A inhibitors. We discovered T-773 as a candidate PET radioligand for PDE10A and investigated its properties by in vitro autoradiography and a PET study in a monkey.
METHODS: Profiling of T-773 as a PET radioligand for PDE10A was conducted by in vitro enzyme inhibitory assay, in vitro autoradiography, and PET study in a monkey.
RESULTS: T-773 showed a high binding affinity and selectivity for human recombinant PDE10A2 in vitro; the IC50 value in an enzyme inhibitory assay was 0.77nmol/L, and selectivity over other PDEs was more than 2500-fold. In autoradiography studies using mouse, rat, monkey, or human brain sections, radiolabeled T-773 selectively accumulated in the striatum. This selective accumulation was not observed in the brain sections of Pde10a-KO mice. The binding of [(3)H]T-773 to PDE10A in rat brain sections was competitively inhibited by MP-10, a selective PDE10A inhibitor. In rat brain sections, [(3)H]T-773 bound to a single high affinity site of PDE10A with Kd values of 12.2±2.2 and 4.7±1.2nmol/L in the caudate-putamen and nucleus accumbens, respectively. In a monkey PET study, [(11)C]T-773 showed good brain penetration and striatum-selective accumulation.
CONCLUSION: These results suggest that [(11)C]T-773 is a potential PET radioligand for PDE10A.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoradiography; C-11; PDE10A; PET; T-773

Mesh:

Substances:

Year:  2014        PMID: 25451212     DOI: 10.1016/j.nucmedbio.2014.09.005

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  11 in total

Review 1.  TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Authors:  Kazunori Suzuki; Haruhide Kimura
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

2.  Molecular Imaging of PDE10A Knockout Mice with a Novel PET Radiotracer: [(11)C]T-773.

Authors:  Miklós Tóth; Jenny Häggkvist; Vladimir Stepanov; Akihiro Takano; Ryuji Nakao; Nahid Amini; Shotaro Miura; Haruhide Kimura; Takahiko Taniguchi; Balázs Gulyás; Christer Halldin
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

3.  Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.

Authors:  Junfeng Li; Xiang Zhang; Hongjun Jin; Jinda Fan; Hubert Flores; Joel S Perlmutter; Zhude Tu
Journal:  J Med Chem       Date:  2015-10-15       Impact factor: 7.446

4.  Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject.

Authors:  Hui Liu; Hongjun Jin; Xuyi Yue; Xiang Zhang; Hao Yang; Junfeng Li; Hubert Flores; Yi Su; Joel S Perlmutter; Zhude Tu
Journal:  Neuroimage       Date:  2015-07-26       Impact factor: 6.556

5.  TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.

Authors:  Kazunori Suzuki; Akina Harada; Hirobumi Suzuki; Maki Miyamoto; Haruhide Kimura
Journal:  Neuropsychopharmacology       Date:  2016-02-05       Impact factor: 7.853

6.  Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.

Authors:  Akina Harada; Kazunori Suzuki; Naomi Kamiguchi; Maki Miyamoto; Kimio Tohyama; Kosuke Nakashima; Takahiko Taniguchi; Haruhide Kimura
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

7.  A novel thermoregulatory role for PDE10A in mouse and human adipocytes.

Authors:  Mohammed K Hankir; Mathias Kranz; Thorsten Gnad; Juliane Weiner; Sally Wagner; Winnie Deuther-Conrad; Felix Bronisch; Karen Steinhoff; Julia Luthardt; Nora Klöting; Swen Hesse; John P Seibyl; Osama Sabri; John T Heiker; Matthias Blüher; Alexander Pfeifer; Peter Brust; Wiebke K Fenske
Journal:  EMBO Mol Med       Date:  2016-07-01       Impact factor: 12.137

8.  Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potential for the treatment of schizophrenia.

Authors:  Keita Arakawa; Shunsuke Maehara; Natsuko Yuge; Makoto Ishikawa; Yutaka Miyazaki; Hiroyasu Naba; Yutaka Kato; Kazunari Nakao
Journal:  Pharmacol Res Perspect       Date:  2016-06-10

9.  Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents.

Authors:  Akina Harada; Nidhi Kaushal; Kazunori Suzuki; Atsushi Nakatani; Konstantin Bobkov; John A Vekich; Joseph P Doyle; Haruhide Kimura
Journal:  Int J Neuropsychopharmacol       Date:  2020-02-01       Impact factor: 5.176

10.  Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor.

Authors:  Thomas A Macek; Kazunori Suzuki; Karen Asin; Haruhide Kimura
Journal:  Int J Neuropsychopharmacol       Date:  2020-11-26       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.